Você esta aqui:Home > Therapeutics (antigo) > Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists

J Cannabis Ther 2002(3/4):143-152

Tourette Syndrome

Combined Treatment of Tourette Syndrome with Delta-9-THC and Dopamine Receptor Antagonists

Author
KR Müller-Vahl, U Schneider, HM Emrich

Abstract
Animal studies suggest that cannabinoid receptor agonists might enhance the effect of dopamine receptor antagonists (neuroleptics, NL) in hyperkinetic movement disorders. In Tourette syndrome, NL are the most effective drugs for the treatment of tics. Recent clinical trials demonstrated that delta-9-tetrahydrocannabinol (delta-9-THC) also produces a tic-suppressing effect. In this single case study in a 24 years old female suffering from TS with extreme tics, it is suggested for the first time that delta-9-THC may be useful in augmenting the pharmacological response to atypical NL such as amisulpride and risperidone in TS patients. No serious adverse reactions occurred. Controlled studies are necessary to confirm this initial report.


Keywords
Tourette syndrome, tics, cannabis, THC, amisulpride, neuroleptics

PDF do texto completo ]

Eventos Online 2020

Todas as informações sobre os Eventos IACM Online, incluindo vídeos gratuitos dos webinars com legendas em português, podem ser encontradas aqui.

Conferência 2021

A 12ª Conferência da IACM sobre Canabinóides em Medicina terá lugar online de 14 a 16 de Outubro de 2021. A inscrição é gratuita.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.